Taiwanese drug developer Senhwa Biosciences said Sunday that its investigational drug for the treatment of severe COVID-19 infections has received positive reviews from an independent monitoring group in the United States, and its clinical trials can go forward.
(Full text of the story is now in CNA English news archive. To view the full story, you will need to be a subscribed member of the CNA archive. To subscribe, please read here.)
Latest
- Business
U.S. dollar down in Taipei trading
10/05/2026 10:12 AM - Society
Taiwan headline news
10/05/2026 10:05 AM - Business
Taiwan shares open higher
10/05/2026 09:09 AM - Society
Gender groups urge investigation into 'discriminatory' gay bar raid
10/04/2026 07:48 PM - Society
Drug offenders as a share of Taiwan's prison population falls
10/04/2026 07:42 PM